CAMLINFINE - Camlin Fine Sciences Ltd Share Price

Chemicals & Petrochemicals

₹257.25-12.75(-4.72%)

Market Closed as of Aug 6, 2025, 15:30 IST

Select time range

Valuation
Market Cap	5.07 kCr
Price/Earnings (Trailing)	-32.56
Price/Sales (Trailing)	2.96
EV/EBITDA	148.41
Price/Free Cashflow	-322.68
MarketCap/EBT	-37.35
Enterprise Value	5.62 kCr

Fundamentals
Revenue (TTM)	1.71 kCr
Rev. Growth (Yr)	9.7%
Earnings (TTM)	-158.12 Cr
Earnings Growth (Yr)	100.1%

Profitability
Operating Margin	1%
EBT Margin	-8%
Return on Equity	-18.08%
Return on Assets	-7.81%
Free Cashflow Yield	-0.31%

Price to Sales Ratio

Latest reported: 3

Revenue (Last 12 mths)

Latest reported: 2 kCr

Net Income (Last 12 mths)

Latest reported: -158 Cr

Growth & Returns
Price Change 1W	11.3%
Price Change 1M	-11.5%
Price Change 6M	94.6%
Price Change 1Y	148.2%
3Y Cumulative Return	32.7%
5Y Cumulative Return	26.3%
7Y Cumulative Return	17.6%
10Y Cumulative Return	10.1%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-75.35 Cr
Cash Flow from Operations (TTM)	26.72 Cr
Cash Flow from Financing (TTM)	72.44 Cr
Cash & Equivalents	104.07 Cr
Free Cash Flow (TTM)	-15.72 Cr
Free Cash Flow/Share (TTM)	-0.84

Balance Sheet
Total Assets	2.02 kCr
Total Liabilities	1.15 kCr
Shareholder Equity	874.78 Cr
Current Assets	1.18 kCr
Current Liabilities	846.21 Cr
Net PPE	592.56 Cr
Inventory	526.86 Cr
Goodwill	47.47 Cr

Capital Structure & Leverage
Debt Ratio	0.32
Debt/Equity	0.74
Interest Coverage	-2.36
Interest/Cashflow Ops	1.27

Dividend & Shareholder Returns
Dividend Yield	0.15%
Shares Dilution (1Y)	12.2%
Shares Dilution (3Y)	19.7%

Risk & Volatility
Max Drawdown	-50.7%
Drawdown Prob. (30d, 5Y)	57.31%
Risk Level (5Y)	53.4%

Pros

Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.

Balance Sheet: Strong Balance Sheet.

Size: Market Cap wise it is among the top 20% companies of india.

Past Returns: Outperforming stock! In past three years, the stock has provided 32.7% return compared to 12.3% by NIFTY 50.

Cons

Dilution: Company has a tendency to dilute it's stock investors.

Technicals: SharesGuru indicator is Bearish.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Dividend Yield	0.15%
Shares Dilution (1Y)	12.2%
Earnings/Share (TTM)	-8.29

Financial Health
Current Ratio	1.4
Debt/Equity	0.74

Technical Indicators
RSI (14d)	38.36
RSI (5d)	86.61
RSI (21d)	36.98
MACD Signal	Sell
Stochastic Oscillator Signal	Hold
Grufity Signal	Sell
RSI Signal	Hold
RSI5 Signal	Sell
RSI21 Signal	Hold
SMA 5 Signal	Buy
SMA 10 Signal	Buy
SMA 20 Signal	Sell
SMA 50 Signal	Sell
SMA 100 Signal	Sell

Summary of Latest Earnings Report from Camlin Fine Sciences

Summary of Camlin Fine Sciences's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated:

For the fiscal year ended March 31, 2025, management of Camlin Fine Sciences Limited provided a positive outlook despite challenging global conditions. The company reported consolidated revenue of INR 1,666 crores, marking a 15% growth in core business year-on-year. They attributed this growth to strong performance in their Blends and vanillin segments, which saw significant volume increases. The Blends business specifically grew by approximately 17-18%, reaching INR 878 crores, aided by the acquisition of CFS Vitafor.

Management highlighted that the EBITDA from the core business improved to INR 208 crores, a rise from INR 184 crores in the previous fiscal year, reflecting a margin maintenance even when product prices faced downward pressure. The company anticipates continued volume growth due to the ramp-up of vanillin production and an expected reduction in cash burn from discontinued operations, projected to decrease from INR 22-23 crores to around INR 8 crores per quarter.

Management forecasts that vanillin capacity utilization could reach 100% within two years, driven by market dynamics and anti-dumping duties leading to higher prices in the U.S. and Europe, where they expect a 10 to 15% price increase. They also expressed confidence that the Blends business could maintain a growth trajectory of around 20% over the next few years, particularly after their planned acquisition of Vinpai.

In summary, the management is optimistic about future growth driven by strategic acquisitions, an improvement in production capacity, and market conditions favoring their products.

Q&A Session

Last updated:

Here are the major questions and answers from the Q&A section of the Camlin Fine Sciences earnings transcript, along with specific details provided:

Question: "Could you share the volume of vanillin exports to the U.S. for March and April? Also, what about the recent ADD and CVD duties on Chinese producers?" Answer: "Unfortunately, I'm unable to share specific data due to its competitive nature. However, we've seen overall growth in volumes. The ADD is typically fixed for 5 years, aligning with standard practices."
Question: "What is the current vanillin price difference between Europe and the U.S.?" Answer: "The difference in vanillin prices is approximately 20% to 25%, with U.S. prices being higher. As of now, the U.S. prices are roughly in the range of $15."
Question: "What is the capacity utilization of the vanillin plant, and where do you see this in 2 years?" Answer: "Currently, we are at about 45% to 50% capacity utilization with a goal to reach 100% in the next 2 years as market conditions improve."
Question: "What is the outlook on the blends business' run rate in terms of EBITDA?" Answer: "We anticipate a growth rate of about 20% for the blends business over the next 2 to 3 years, with EBITDA margins expected to be in the high teens."
Question: "Are you facing any pricing pressure on products?" Answer: "Yes, we are experiencing pricing pressure across all products due to increased competition, except for vanillin."
Question: "What will the discontinued losses be in the next financial year?" Answer: "We project that discontinued losses will drop to around INR 8 crores in Q1 FY '26, as we continue to reduce operating costs associated with the abandoned plants."
Question: "What is your cost of production for vanillin?" Answer: "Currently, our production cost for vanillin stands between $9.50 to $10. We expect this to decrease as capacity utilization improves."
Question: "What is the estimated EBITDA margin range for different business segments?" Answer: "While we can't disclose specific figures for all segments, blends generally yield around a 20% margin, whereas other product lines fluctuate significantly."
Question: "What is the timeline for the Vinpai acquisition?" Answer: "We anticipate completing the regulatory procedures by the end of July, which would potentially enhance our growth avenues."

These questions reflect key areas of concern and focus for the company, particularly regarding product pricing, capacity utilization, and financial performance forecasts.

Share Holdings

Understand Camlin Fine Sciences ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
Ashish Subhash Dandekar	10.52%
Infinity Direct Holdings	10.41%
Anfima Nv	9.03%
Infinity Holdings	6.34%
Infinity Direct Capital (erstwhile Infinity Direct Holdings Sidecar I )	4.93%
Camart Finance Limited	2.83%
Nirmal Vinod Momaya	1.92%
Anagha Subhash Dandekar	1.61%
Vibha Agencies Pvt Ltd	1.39%
Ajay Upadhyaya	1.3%
Franklin India Multi Cap Fund	1.21%
Infinity Portfolio Holdings	1.2%
ICICI Prudential Commodities Fund	1.04%
Jagdish N Master	1.02%
Urjita J Master	1.02%
Cafco Consultants Limited	0.8%
Radha Pandit	0.04%
Anand Y Pandit	0.01%
MK Falcon Agro tech Pvt. Ltd.	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Is Camlin Fine Sciences Better than it's peers?

Detailed comparison of Camlin Fine Sciences against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
VINATIORGA	Vinati Organics	18.12 kCr	2.29 kCr	-10.10%	-19.50%	44.72	7.9	-	-
JUBLINGREA	Jubilant Ingrevia	11.64 kCr	4.23 kCr	-7.30%	+19.80%	41.62	2.75	-	-
GALAXYSURF	Galaxy Surfactants	9.04 kCr	4.25 kCr	-1.50%	-9.10%	29.65	2.13	-	-
BALAMINES	Balaji Amines	4.93 kCr	1.43 kCr	-15.40%	-33.40%	32.4	3.51	-	-
SEQUENT	Sequent Scientific	4.48 kCr	1.57 kCr	-5.00%	+33.60%	205.88	2.86	-	-

Sector Comparison: CAMLINFINE vs Chemicals & Petrochemicals

Comprehensive comparison against sector averages

Comparative Metrics

CAMLINFINE metrics compared to Chemicals

Category	CAMLINFINE	Chemicals
PE	-32.56	51.70
PS	2.96	4.57
Growth	5.3 %	7.9 %

Performance Comparison

CAMLINFINE vs Chemicals (2021 - 2025)

Key Insights

1. CAMLINFINE is NOT among the Top 10 largest companies in Specialty Chemicals.
2. The company holds a market share of 1.2% in Specialty Chemicals.
3. In last one year, the company has had a below average growth that other Specialty Chemicals companies.

Income Statement for Camlin Fine Sciences

Consolidated figures (in Rs. Crores) / View Standalone Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	3.3%	1,667	1,613	1,682	1,412	1,187	1,049
Other Income	-13.3%	14	16	5.8	33	4.98	3.43
Total Income	3.2%	1,681	1,629	1,687	1,445	1,192	1,053
Cost of Materials	5.2%	786	747	856	728	488	500
Purchases of stock-in-trade	3.5%	118	114	61	45	78	53
Employee Expense	7.3%	192	179	163	145	120	100
Finance costs	67.8%	100	60	58	36	38	43
Depreciation and Amortization	-19.2%	64	79	63	56	44	33
Other expenses	-6.7%	417	447	500	355	301	285
Total Expenses	-3.3%	1,622	1,678	1,597	1,351	1,087	994
Profit Before exceptional items and Tax	215%	59	-49.44	90	94	105	58
Exceptional items before tax	78.7%	-9.82	-49.8	-9.68	0	0	0
Total profit before tax	147.9%	49	-99.24	80	94	105	58
Current tax	70.8%	42	25	29	32	27	25
Deferred tax	-112.7%	-42.06	-19.24	12	1.53	12	3.48
Total tax	-120.1%	0.07	5.63	41	34	40	28
Total profit (loss) for period	-50.3%	-158.12	-104.88	40	60	65	30
Other comp. income net of taxes	-177.8%	-12.23	18	20	-7.77	114	1.3
Total Comprehensive Income	-94.9%	-170.35	-86.91	60	53	179	31
Earnings Per Share, Basic	-37.2%	-8.03	-5.58	3.45	4.65	4.13	2.5
Earnings Per Share, Diluted	-37.5%	-7.94	-5.5	3.41	4.56	3.68	2.5
Debt equity ratio	-	0.72	0	-	0	0	0
Debt service coverage ratio	-	0.01	0	-	0	0	0

Description	(%) Q/Q	Mar-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023
Revenue From Operations	0.9%	437	433	423	396	402	386
Other Income	2426.5%	9.59	1.34	12	1.87	5.76	1.66
Total Income	2.8%	447	435	435	398	407	388
Cost of Materials	12.8%	195	173	223	215	137	156
Purchases of stock-in-trade	-96.9%	2.36	45	54	16	43	39
Employee Expense	-3.9%	50	52	52	51	46	45
Finance costs	-54.5%	16	34	26	23	16	14
Depreciation and Amortization	30.8%	18	14	21	20	20	21
Other expenses	-2.6%	113	116	108	108	107	104
Total Expenses	-4.6%	413	433	427	421	451	397
Profit Before exceptional items and Tax	6246.2%	34	1.52	8.23	-23.48	-43.7	-9.73
Exceptional items before tax	-	-5.59	0	-151.04	0	-49.8	0
Total profit before tax	5284.6%	29	1.52	-142.81	-23.48	-93.51	-9.73
Current tax	291.6%	14	4.32	16	7.4	6.51	6.48
Deferred tax	-486.8%	-6.04	2.82	-42.61	3.77	-18.23	-1.94
Total tax	13.2%	7.95	7.14	-26.2	11	-11.72	4.55
Total profit (loss) for period	89.5%	0.11	-7.47	-116.11	-34.65	-81.79	-14.28
Other comp. income net of taxes	136.5%	5.79	-12.11	0.03	-5.95	-0.92	16
Total Comprehensive Income	123.8%	5.9	-19.58	-116.08	-40.6	-82.71	2.11
Earnings Per Share, Basic	16.3%	-0.04	-0.243	-5.98	-2.03	-4.64	-0.71
Earnings Per Share, Diluted	16.1%	-0.04	-0.24	-5.93	-2.01	-4.58	-0.7
Debt equity ratio	-	0.72	-	-	0	0	0
Debt service coverage ratio	-	0.01	-	-	0	0	0

Standalone figures (in Rs. Crores) / View Consolidated Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	14.6%	886	773	789	686	600	580
Other Income	11.1%	21	19	29	19	5.47	24
Total Income	14.5%	907	792	818	704	606	604
Cost of Materials	26.6%	539	426	403	382	384	377
Purchases of stock-in-trade	114.5%	17	8.46	5.54	7.62	16	13
Employee Expense	9.2%	72	66	60	53	39	28
Finance costs	22.6%	66	54	57	33	33	28
Depreciation and Amortization	8.3%	53	49	33	27	19	11
Other expenses	10.6%	262	237	236	161	121	103
Total Expenses	10%	935	850	752	668	590	559
Profit Before exceptional items and Tax	51.6%	-27.43	-57.7	67	36	16	44
Exceptional items before tax	-3210.6%	-96	-1.93	0	0	-0.5	-3.14
Total profit before tax	-105.2%	-123.43	-59.63	67	36	15	41
Current tax	-	1.66	0	14	6.4	2.78	7.5
Deferred tax	-438.7%	-48.78	-8.24	5.15	3.81	3.96	3.06
Total tax	-420.8%	-47.12	-8.24	19	10	6.74	11
Total profit (loss) for period	-47.6%	-76.31	-51.39	48	26	8.28	31
Other comp. income net of taxes	-48.1%	-0.54	-0.04	-0.66	-0.15	-0.38	-0.29
Total Comprehensive Income	-48.5%	-76.85	-51.43	47	26	7.9	30
Earnings Per Share, Basic	-32.3%	-4.41	-3.09	3.18	1.98	0.67	2.53
Earnings Per Share, Diluted	-32.3%	-4.36	-3.05	3.14	1.94	0.6	2.53
Debt equity ratio	-	051	0	0	0	0	0
Debt service coverage ratio	-	077	0	0	0	0	0

Description	(%) Q/Q	Mar-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023
Revenue From Operations	33.3%	273	205	227	182	220	186
Other Income	54.6%	10	6.82	3.08	1.78	5.55	2.13
Total Income	33.6%	283	212	230	184	226	188
Cost of Materials	41.9%	150	106	151	132	108	104
Purchases of stock-in-trade	19.2%	0.58	0.48	14	2.26	3.88	1.02
Employee Expense	12.5%	19	17	20	17	17	16
Finance costs	0%	17	17	18	14	14	13
Depreciation and Amortization	0%	13	13	13	13	13	12
Other expenses	5.8%	74	70	63	56	64	56
Total Expenses	23.9%	271	219	244	201	273	205
Profit Before exceptional items and Tax	234.3%	12	-7.19	-14.27	-17.6	-46.75	-17.69
Exceptional items before tax	-	0.26	0	-96.27	0	-1.93	0
Total profit before tax	234.3%	12	-7.19	-110.54	-17.6	-48.68	-17.69
Current tax	-	0	0	5.44	-3.78	-0.63	-1.33
Deferred tax	-83.7%	-3.72	-1.57	-43.36	-0.13	-3.98	-4.72
Total tax	-83.7%	-3.72	-1.57	-37.91	-3.92	-4.61	-6.05
Total profit (loss) for period	326.2%	16	-5.63	-72.62	-13.68	-44.07	-11.64
Other comp. income net of taxes	128.3%	1.94	-2.32	-0.72	0.55	-0.22	-0.09
Total Comprehensive Income	289.9%	18	-7.95	-73.34	-13.13	-44.3	-11.73
Earnings Per Share, Basic	89.5%	0.86	-0.33	-4.34	-0.82	-2.65	-0.7
Earnings Per Share, Diluted	88.7%	0.85	-0.327	-4.29	-0.81	-2.61	-0.69
Debt equity ratio	-	051	-	-	0	0	0
Debt service coverage ratio	-	077	-	-	0	0	0

Balance Sheet for Camlin Fine Sciences

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022
Cash and cash equivalents	30.4%	104	80	80	92	94	86
Current investments	-	38	0	0	0	0	0
Loans, current	576.7%	10	2.33	10	10	10	0.06
Total current financial assets	28.3%	532	415	391	358	418	451
Inventories	5.2%	527	501	513	591	568	433
Total current assets	16.1%	1,183	1,019	999	1,047	1,086	944
Property, plant and equipment	1.7%	593	583	757	780	794	505
Capital work-in-progress	-58.4%	9.73	22	46	50	41	330
Investment property	-	2.16	0	0	0	0	0
Goodwill	-38.7%	47	76	47	53	53	53
Non-current investments	0%	23	23	7.88	7.88	7.96	7.23
Total non-current financial assets	-2.7%	37	38	22	22	25	22
Total non-current assets	-2.8%	840	864	951	965	972	981
Total assets	7.4%	2,024	1,885	1,952	2,014	2,060	1,927
Borrowings, non-current	-21.5%	268	341	333	351	408	369
Total non-current financial liabilities	-13.8%	294	341	350	369	423	402
Provisions, non-current	-2.4%	5.48	5.59	5.11	4.77	4.81	3.47
Total non-current liabilities	-17.9%	303	369	362	390	443	421
Borrowings, current	-5.5%	377	399	325	315	371	370
Total current financial liabilities	4.3%	817	783	690	628	730	693
Provisions, current	11.1%	11	10	9.58	9.45	10	8.2
Current tax liabilities	5.2%	2.21	2.15	0.19	6.9	14	13
Total current liabilities	-0.6%	846	851	732	681	793	745
Total liabilities	-5.8%	1,149	1,220	1,095	1,071	1,236	1,166
Equity share capital	12.5%	19	17	17	17	16	16
Non controlling interest	-9.5%	-26.89	-24.47	-7.8	-0.76	4.71	11
Total equity	31.6%	875	665	857	942	824	761
Total equity and liabilities	7.4%	2,024	1,885	1,952	2,014	2,060	1,927

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022
Cash and cash equivalents	4645.5%	36	0.23	0.68	0.14	22	16
Current investments	-	38	0	0	0	0	0
Loans, current	3.6%	59	57	52	43	30	33
Total current financial assets	33.6%	629	471	582	564	549	613
Inventories	4.4%	263	252	255	281	142	174
Total current assets	24.2%	929	748	858	864	718	811
Property, plant and equipment	0.8%	520	516	560	564	282	285
Capital work-in-progress	-64.8%	9.1	24	31	35	207	321
Investment property	-	2.16	0	0	0	0	0
Non-current investments	0%	64	64	80	82	82	82
Loans, non-current	-	0	0	4.69	12	6.8	8.73
Total non-current financial assets	0%	67	67	88	98	95	95
Total non-current assets	-1%	699	706	711	724	625	729
Total assets	11.9%	1,629	1,456	1,572	1,590	1,346	1,542
Borrowings, non-current	-11.9%	172	195	222	237	258	257
Total non-current financial liabilities	-6.7%	182	195	237	252	268	266
Provisions, non-current	-2.7%	5.32	5.44	4.97	4.65	3.32	3.47
Total non-current liabilities	-12.7%	187	214	249	272	282	285
Borrowings, current	-13.8%	270	313	269	244	190	307
Total current financial liabilities	0.4%	567	565	580	506	442	602
Provisions, current	10.3%	3.35	3.13	3.02	2.48	1.7	1.33
Current tax liabilities	-	-	0.01	0	6.25	5.62	12
Total current liabilities	-5.4%	580	613	607	546	472	639
Total liabilities	-7.3%	766	826	856	818	754	924
Equity share capital	12.5%	19	17	17	17	16	16
Total equity	36.9%	862	630	716	772	592	618
Total equity and liabilities	11.9%	1,629	1,456	1,572	1,590	1,346	1,542

Cash Flow for Camlin Fine Sciences

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	67.8%	100	60	58	36	-	-
Depreciation	-6.4%	74	79	63	56	-	-
Impairment loss / reversal	-	146	0	9.68	0	-	-
Unrealised forex losses/gains	-30.6%	26	37	-8.88	-16.96	-	-
Adjustments for interest income	-534.8%	0	1.23	0.73	1.56	-	-
Share-based payments	-1%	0	0.01	2.36	7.39	-	-
Net Cashflows from Operations	-65.6%	65	187	71	176	-	-
Income taxes paid (refund)	-21.3%	38	48	20	30	-	-
Net Cashflows From Operating Activities	-81.2%	27	139	51	145	-	-
Cashflows used in obtaining control of subsidiaries	-	0	0	0	66	-	-
Cash payment for investment in partnership firm or association of persons or LLP	-	31	0	0	0	-	-
Proceeds from sales of PPE	-127.3%	0	0.56	0.9	0	-	-
Purchase of property, plant and equipment	-31.7%	42	61	144	214	-	-
Dividends received	-	0.82	0	0	0	-	-
Interest received	-160.9%	0.86	1.23	0.73	1.7	-	-
Other inflows (outflows) of cash	42%	-4.05	-7.71	29	28	-	-
Net Cashflows From Investing Activities	-13.1%	-75.35	-66.5	-124.63	-249.13	-	-
Proceeds from issuing shares	-	223	0	0	95	-	-
Proceeds from exercise of stock options	-92.9%	0.19	0.58	0.55	0	-	-
Proceeds from borrowings	-104.2%	0	25	81	106	-	-
Repayments of borrowings	-	71	0	-52.27	30	-	-
Payments of lease liabilities	-10%	10	11	8.22	8.83	-	-
Interest paid	-4.2%	70	73	52	25	-	-
Other inflows (outflows) of cash	96.6%	0	-28.13	-13.85	-0.71	-	-
Net Cashflows from Financing Activities	181.6%	72	-85.97	60	136	-	-
Net change in cash and cash eq.	258.7%	24	-13.49	-14.07	32	-	-

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	22.6%	66	54	57	33	-	-
Change in inventories	97.7%	0	-41.67	0	0	-	-
Depreciation	8.3%	53	49	33	27	-	-
Unrealised forex losses/gains	1.8%	6.78	6.68	-19.23	-5.75	-	-
Adjustments for interest income	39.6%	6.22	4.74	4.1	4.11	-	-
Share-based payments	-	0	0	2.34	7.36	-	-
Net Cashflows from Operations	-77.8%	23	100	26	48	-	-
Income taxes paid (refund)	-98.8%	1.2	18	7.39	1.15	-	-
Net Cashflows From Operating Activities	-74.1%	22	82	19	47	-	-
Cashflows used in obtaining control of subsidiaries	-	0	0	0	6.55	-	-
Cash payment for investment in partnership firm or association of persons or LLP	-	31	0	0	0	-	-
Proceeds from sales of PPE	93.5%	0.94	0.08	0	0	-	-
Purchase of property, plant and equipment	-45%	23	41	131	189	-	-
Interest received	87.5%	0.94	0.52	0.65	1.61	-	-
Other inflows (outflows) of cash	-305.9%	-34.72	-7.8	29	28	-	-
Net Cashflows From Investing Activities	-68.2%	-87.66	-51.72	-114.73	-172.33	-	-
Proceeds from issuing shares	-	223	0	0	95	-	-
Proceeds from exercise of stock options	-138.1%	0	0.58	0.55	0	-	-
Proceeds from borrowings	-107.7%	0	14	121	88	-	-
Repayments of borrowings	14900%	61	1.4	0	21	-	-
Payments of lease liabilities	-	7.73	0	3.98	2.25	-	-
Interest paid	15.2%	54	47	39	31	-	-
Net Cashflows from Financing Activities	385.3%	101	-34.05	78	129	-	-
Net change in cash and cash eq.	828.1%	35	-3.67	-17.82	3.39	-	-

What does Camlin Fine Sciences Ltd do?

Specialty Chemicals•Chemicals•Small Cap

Industry Group:Chemicals & Petrochemicals

Employees:624

Website:www.camlinfs.com

CAMLINFINE - Camlin Fine Sciences Ltd Share Price

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Risk & Volatility

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Camlin Fine Sciences Ltd do?